Arcutis Biotherapeutics, Inc. Q3 2025 Earnings Recap

ARQT Q3 2025 October 28, 2025

Get alerts when ARQT reports next quarter

Arcutis Biotherapeutics reported robust Q3 2025 results, with net product revenues of $99.2 million, reflecting a substantial 122% year-over-year increase driven by strong demand for its ZORYVE portfolio.

Earnings Per Share Beat

$0.06 vs $-0.10 est.

+160.0% surprise

Revenue Miss

99219000 vs 110794170 est.

-10.4% surprise

Market Reaction

1-Day +27.04%

5-Day +28.87%

30-Day +50.15%

See ARQT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net product revenues increased 22% sequentially and 122% compared to Q3 2024, fueled by growing prescription volumes across ZORYVE formulations.
Total prescriptions for ZORYVE rose 13% from Q2 and 92% year-over-year, reaching record weekly averages with over 17,000 scripts.
The recent launch of ZORYVE cream 0.05% for atopic dermatitis (ages 2-5) is expected to further drive sales in the upcoming quarter.
R&D expenses remain stable year-over-year at $19.6 million, with anticipated increases in 2026 for further clinical developments.
Arcutis is nearing cash flow positivity, enabling sustained business investments and growth in the dermatology sector.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ARQT on AllInvestView.